Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
RUA Life Sciences ( (GB:RUA) ) just unveiled an announcement.
RUA Life Sciences has reported an update on its French subsidiary, ABISS, which was acquired in September 2024. Despite initial supply chain challenges, ABISS achieved a significant turnaround in financial performance, recording revenues of €2.3 million and a profit before tax of €46k for the year ending December 2024. This represents a substantial improvement from the previous year’s loss and positions ABISS for further growth, particularly in the European market for its Cyrene product range. The acquisition bolsters RUA’s strategic opportunities in developing its group capabilities.
More about RUA Life Sciences
RUA Life Sciences is a holding company for a group of medical device businesses focusing on exploiting a patented biostable polyurethane polymer known as Elast-Eon™. The group aims to enhance patient lives through medical devices that utilize this polymer, which is renowned for its mechanical and biostability properties, akin to silicone. RUA Life Sciences operates through four business units: RUA Contract Manufacture, RUA Biomaterials, RUA Vascular, and RUA Structural Heart, each specializing in different aspects of medical device manufacturing and development.
YTD Price Performance: 13.64%
Average Trading Volume: 246,268
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.76M
See more insights into RUA stock on TipRanks’ Stock Analysis page.
